ReviewAnnals of oncology : official journal of the European Society for Medical Oncology2017
Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.
Review in Annals of oncology : official journal of the European Society for Medical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- A target map of clinical combination therapies in oncology: an analysis of clinicaltrials.gov.Discover oncology · 2023Article
- Identification of m7G-Related miRNA Signatures Associated with Prognosis, Oxidative Stress, and Immune Landscape in Lung Adenocarcinoma.Biomedicines · 2023Article
- Prognostic necroptosis-related gene signature aids immunotherapy in lung adenocarcinoma.Frontiers in genetics · 2022Article
- pH-Sensitive and Charge-Reversal Polymeric Nanoplatform Enhanced Photothermal/Photodynamic Synergistic Therapy for Breast Cancer.Frontiers in bioengineering and biotechnology · 2022Article
- Long Non-Coding RNAs (lncRNAs) in Response and Resistance to Cancer Immunosurveillance and Immunotherapy.Cells · 2021Review
- Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.Journal for immunotherapy of cancer · 2021Article
- Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients.Journal for immunotherapy of cancer · 2021Observational
- Immune Resistance in Lung Adenocarcinoma.Cancers · 2021Review
- Photodynamic Therapy for the Treatment and Diagnosis ofFrontiers in chemistry · 2021Review
- Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies.Antibodies (Basel, Switzerland) · 2020Review
- Cell-mediated immune resistance in cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Article
- The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.Therapeutic advances in medical oncology · 2019Review
- New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series.ESMO open · 2019Article
- Antigen presentation of the Oct4 and Sox2 peptides by CD154-activated B lymphocytes enhances the killing effect of cytotoxic T lymphocytes on tumor stem-like cells derived from cisplatin-resistant lung cancer cells.Journal of Cancer · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
In the 1990s, the application of immunotherapy approaches to target cancer cells resulted in significant clinical responses in patients with advanced malignancies who were refractory to conventional therapies. While early immunotherapeutics were focused on T cell-mediated cytotoxic activity, subsequent efforts were centered on targeted antibody-mediated anticancer therapy. The initial success with antibody therapy encouraged further studies and, consequently, there are now more than 25 FDA-approved antibodies directed against a range of targets. Although both T cell and antibody therapies continue to result in significant clinical responses with minimal toxicity, a significant subset of patients does not respond to immunotherapy and another subset develops resistance following an initial response. This review is focused on describing examples showing that cancer resistance to immunotherapies indeed occurs. In addition, it reviews the mechanisms being used to overcome the resistance to immunotherapies by targeting the tumor cell directly and/or the tumor microenvironment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.